RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer
5 May, 2023 | 15:13h | UTCTrifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD pic.twitter.com/gHTR9jbJS5
— NEJM (@NEJM) May 3, 2023